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1. Introduction  
Psoriasis is a chronic, inflammatory disease affecting the skin and potentially the joints. Both 
genetic and environmental factors are important in the etiology of the disease. Psoriasis is 
characterized by keratinocyte hyperproliferation, abnormal keratinocyte differentiation, and 
immune-cell infiltration into the epidermis and dermis.  
Disease management is dependent on severity, psychosocial effects and the patient's 
lifestyle. Currently, psoriasis may be treated with phototherapy or by using various topical, 
systemic, and biologic drug treatments. Topical treatments include creams and ointments 
containing tar, dithranol, corticosteroids, salicylic acid or vitamin D-related compounds.  
Vitamin D3 analogs inhibit proliferation, induce terminal differentiation of human 
keratinocytes and exhibit immunomodulating properties. Several studies have shown 
vitamin D analogs to be a safe, efficacious and long-term treatment option for psoriasis. 
Vitamin D3 analogs are also used in combination with phototherapy. 
Phototherapy (broadband UVB, narrowband UVB (NBUVB) and heliotherapy – treatment 
with natural sunlight) is a commonly used treatment modality for widespread psoriasis. A 
similar wavelength spectrum of UVB (280-315 nm) is responsible for vitamin D synthesis in 
the skin. Vitamin D3, or cholecalciferol, is produced from 7-dehydrocholesterol in the basal 
epidermis when exposed to UVB, and is then hydroxylated in the liver into 25-
hydroxyvitamin D [25(OH)D], which is the major circulating metabolite. Further 
hydroxylation into 1,25-dihydroxyvitamin D [1,25(OH)2D] occurs primarily in the kidneys. 
Hydroxylation in the kidneys is stimulated by parathyroid hormone (PTH) and suppressed 
by phosphate. Homeostatic mechanisms include parathyroid activity, serum calcium and 
serum 1,25(OH)2D3 itself. Vitamin D is an essential steroid not only for calcium homeostasis 
and skeletal health, but also for regulation of cellular growth, cell proliferation and cell 
differentiation. Vitamin D is obtained by skin production in response to UVB or by intake of 
vitamin D rich food or supplements. Vitamin D status is measured by serum/blood 
concentration of its metabolite 25(OH)D.  
The wavelength spectrum of UVB responsible for vitamin D synthesis (broadband UVB, 
290-320 nm) has been used successfully for years to treat psoriasis and other chronic 
inflammatory skin disorders. This chapter aims to increase knowledge about the effects of 
UVB on vitamin D production during treatment with phototherapy in patients with 
psoriasis and to investigate the impact of UVB-induced vitamin D on psoriasis, bone, lipid 
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and carbohydrate status in psoriasis patients. A review of the published studies will be used 
to accomplish this task. In our previously published studies, the serum concentrations of 
25(OH)D, 1,25(OH)2D, PTH, calcium and creatinine were measured before and after 
phototherapy in Caucasian patients with moderate to severe active plaque psoriasis. Bone 
mineral density (BMD) was examined using dual-energy X-ray absorptiometry (DEXA) at 
the hip and lumbar spine in a group of postmenopausal women with psoriasis. Lipid and 
carbohydrate status were assessed in patients treated with heliotherapy. 
We found that UVB/heliotherapy improved the psoriasis score and lipid and carbohydrate 
status of the patients, increased serum 25(OH)D synthesis and reduced serum PTH 
concentrations. Vitamin D production in psoriasis patients increased less with narrowband 
UVB than with broadband UVB phototherapy. There was no correlation between the dose of 
UVB and the increase in 25(OH)D. The ratio of low density lipoprotein (LDL) and high 
density lipoprotein (HDL) cholesterol decreased, and the levels of glycosylated hemoglobin 
A1c (HbA1c) also decreased in psoriasis patients during heliotherapy. Postmenopausal 
women with psoriasis had higher BMD than age-matched controls, a finding that could be 
related to their higher body weight, levels of physical activity and UVB exposure.  
The changes in serum concentrations of vitamin D metabolite 25(OH)D were not related to 
the degree of improvement in psoriasis severity. This can be explained by the fact that 
25(OH)D is biologically inert. It is unclear if the serum 25(OH)D level is linked to the level of 
the active form of vitamin D3 (1,25(OH)2D) present in the skin. It has been suggested that 
cutaneous conversion of 25(OH)D to 1,25(OH)2D does not play a role because the amount of 
free 25(OH)D3 that penetrates the cell membrane of epidermal keratinocytes is too small to 
produce sufficient amounts of 1,25(OH)2D. Therefore, of great interest will be the study of 
UVB induced local effects on vitamin D synthesis and metabolism in psoriatic skin.  
2. Content 
2.1 Vitamin D, skin production and metabolism 
Vitamin D or calciferol refers to cholecalciferol or vitamin D3 and ergocalciferol or vitamin 
D2. D3 is produced in the skin as a result of ultraviolet irradiation of  7-dehydrocholesterol 
(7-DHC) and D2 is produced by ultraviolet irradiation of the plant sterol ergosterol(1). 
Vitamin D was discovered in the 1900's as a result of research efforts geared towards the 
treatment of the disease, rickets. Within the last decade, vitamin D has become a popular 
topic in medical research as investigators aim to elucidate the role it plays in both 
maintaining health and contributing to the onset of disease. 
Most people obtain their vitamin D requirement from sunlight exposure (2) in addition to 
smaller amounts obtained through the diet since very few foods naturally contain vitamin D.  
7-DHC absorbs ultraviolet B (UVB) radiation and optimum wavelengths for vitamin D3 
production are between 295 nm and 300 nm with a peak at 297 nm(3). Levels of 7-DHC have 
been observed to decline with age, which might negatively impact vitamin D3 synthesis in 
the skin (2). Vitamin D3 produced in the skin or ingested from the diet can be stored in body 
fat and later released into circulation. Vitamin D3 is sequestered deep into body fat, making 
it less bioavailable in obese individuals(4). Vitamin D is biologically inert and must be 
hydroxylated in the liver to form 25-hydroxyvitamin D [25(OH)D or calcidiol], which is the 
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major circulating metabolite. Further hydroxylation into 1,25-dihydroxyvitamin D 
[1,25(OH)2D or calcitriol] occurs primarily in the kidneys (Figure 1). Hydroxylation in the 
kidneys is stimulated by parathyroid hormone (PTH) and suppressed by phosphate. 
Homeostatic mechanisms include parathyroid activity, serum calcium and serum 
1,25(OH)2D itself. Conversion of vitamin D to 25(OH)D is mediated by the enzyme vitamin 
D-25-hydroxylase (CYP27A1). The synthesis and degradation of calcitriol are regulated by 
the enzymes 25(OH)D-1-ǂ-hydroxylase (CYP27B1) and 25(OH)2D-24-hydroxylase 
(CYP24A1), respectively. The combined activity of these enzymes is an important factor in 
determining the circulating concentrations of 25(OH)D, and 1,25(OH)2D(1). In addition to 
the kidney, other tissues and cells, including keratinocytes and immune cells, contain these 
enzymes and are able to convert 25(OH)D to active 1,25(OH)2D(5). 
Besides being an essential steroid for calcium homeostasis and skeletal health, vitamin D 
also plays a role in regulation of cellular growth, cell proliferation and cell differentiation. 
Vitamin D also regulates the immune system, controls cancer cell growth and plays a role in 
the regulation of blood pressure(6). These effects are mediated through the intracellularly 
located vitamin D receptor (VDR). VDR is a member of the steroid, estrogen and retinoid 
receptor gene family of proteins that mediate transcriptional activities of the respective 
ligands. The VDR complex interacts with vitamin D responsive elements on the target gene. 
Alterations in calcitriol levels and polymorphisms of the VDR gene have been shown to be 
associated with several malignant and autoimmune diseases including psoriasis vulgaris(7).  
25(OH)D is used clinically to measure vitamin D status. The cut-off level for serum 
25(OH)D, which is used as a diagnostic marker for vitamin D deficiency, has varied over the 
years(8-10). The early biochemical changes in vitamin D insufficiency include a rise in serum 
PTH, which begins to increase as serum 25(OH)D levels fall below 30 ng/ml or 75 
nmol/l(9). This level of 25(OH)D has become the suggested cut-off point for vitamin D 
deficiency or inadequacy(9, 11-13). At the present time, there is no clear consensus regarding 
levels of 25(OH)D for optimal health but levels of  > 50 nmol/l (20 ng/ml)(14) and > 75 
nmol/l (30 ng/ml)  have been based on considering the outcomes of bone health, fracture 
prevention and colorectal cancer(15,16). Sun exposure is the strongest factor influencing 
25(OH)D. The serum concentrations of 25(OH)D vary seasonally, with maximum and 
minimum values in the late summer and  winter respectively(17). The extent of this seasonal 
variation depends on factors such as latitude, skin pigmentation, clothing, and the use of 
sunscreen(18).  
Currently, limited data is available on the role of vitamin D deficiency in the pathogenesis or 
outcomes of psoriasis. The lack of conclusive data combined with vitamin D’s 
immunomodulatory role, warrants further research investigating the role of vitamin D 
insufficiency in chronic diseases as well as monitoring 25(OH)D levels in children and 
adults of all ages as a part of routine physical examinations.  
2.2 The effects of vitamin D in psoriasis 
Vitamin D has pleotropic functions; it acts as a hormone by controlling calcium homeostasis 
as well as exerting autocrine/paracrine effects on tissues that express CYP27B1 and VDR. 
Besides its local effects, calcitriol may also act in psoriasis through its immunomodulatory 
properties by inhibiting T-cell proliferation and Th1 development, modulating antigen-
presenting cell (APCs) function, inducing hyporesponsiveness to antigens, inhibiting 
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production of IL-2, IL-17, IL-8 and interferon-Ǆ, increasing the production of IL-10 and 
regulatory T cells(19, 20). Calcitriol has also been suggested to reduce production of 
interferon-ǂ in some cells(21). Calcitriol is involved in the regulation of antimicrobial 
peptides cathelicidin and human ǃ-defensin 2 (HBD2), which both participate in the 
pathogenesis of psoriasis (22). Vitamin D’s role in psoriasis is further supported by studies 
that confirm the link between VDR polymorphism and psoriasis (23, 24). An association 
between VDR genotypes (Apa1) and the mean age at onset of psoriasis were previously 
observed (25). Since VDR gene polymorphisms show ethnic variability, concern arises on 
how to treat psoriasis patients of different populations according to their potentially varied 
treatment response (26). Moreover, it has been demonstrated that VDR gene polymorphisms 
may also play a role in partial resistance to calcipotriol therapy (24). 
There are few studies on high-dose vitamin D3 in the treatment of psoriasis while systemic 
administration of 1,25(OH)2D for the treatment of psoriasis might be limited by its toxicity. 
A number of small trials show the efficacy and safety of vitamin D metabolites in the 
treatment of psoriasis and psoriatic arthritis (27-29). Systemic calcitriol treatment had an 
immunomodulatory effect manifested by a short-term temporary decrease in type 1 immune 
responses and a decrease in disease activity in patients with psoriatic arthropathy (27). 
Administration of vitamin D3 could be a better option than calcitriol or alphacalcidol since it 
is safer and less expensive, although more studies are needed to assess its efficacy (21). 
However, the use of calcitiol in dermatology is hampered by its hypercalcemic activity. 
There is limited information on the role of vitamin D deficiency in the pathogenesis of 
psoriasis or the role of vitamin D deficiency in response to treatments with topical or 
systemic drugs. There is a report of resolution of anti-TNFǂ-induced psoriasiform lesions by 
high doses of vitamin D3, in a patient with rheumatoid arthritis and vitamin D deficiency 
(21). More studies are needed to assess the possible usefulness of high-dose vitamin D3 in 
the treatment of psoriasis.  
2.3 Effects of vitamin D3 analogues in psoriasis 
The observation that keratinocytes and T cells express VDR and that 1,25(OH)2D is a potent 
stimulator of keratinocyte differentiation provides a potential basis for the clinical use of 
VDR ligands for the treatment of psoriasis (30, 31). Clinical data that first supported the use 
of vitamin D analogs was obtained when a patient treated orally with 1-hydroxyvitamin D3 
for osteoporosis showed remarkable remission of psoriatic lesions(32). In addition, 
promising clinical results were obtained in studies using oral 1-hydroxyvitamin D3, oral and 
topical calcitriol which led to improvement of psoriatic lesions in approximately 70-80% of 
patients (33). Vitamin D3 analogs (calcipotriol (Dovonex), calcitriol (Silkis) or tacalcitol 
(Curatoderm)) inhibit proliferation, induce terminal differentiation of human keratinocytes 
and exhibit immunomodulating properties (33). Differentiation of keratinocytes results in 
the formation of a cornified envelope (CE) that provides the barrier function of the skin. The 
expression of involucrin, a component of the CE, and transglutaminase I (TGase I), the 
enzyme that cross-links the components of CE, was increased by calcitriol and other VDR 
ligands(35). Treatment of keratinocytes with a medium containing high calcium also 
stimulated keratinocyte differentiation by increasing the expression of involucrin and TGase 
I. 1,25(OH)2D also promoted keratinocyte differentiation, at least in part by increasing 
intracellular calcium and by increased expression of calcium receptors in keratinocytes(36). 
Calcitriol indirectly induces the expression of keratin 1, involucrin, TGase I, loricrin, and 
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filaggrin, which are required for CE formation. VDR ligands decreased the expression of 
proinflammatory cytokines IL-2, IFN-Ǆ, IL-6, IL-8 (37-40) and proliferation of T lymphocytes 
and keratinocytes. Furthermore, topical calcipotriol increased anti-inflammatory cytokine 
IL-10 in psoriatic lesions(41), and  increased the expression of IL-10 receptor in 
keratinocytes(42).  
Antigen presenting cells (APCs), which play an important role in psoriasis, are one of the 
major targets of calcitriol-mediated immunosuppressive action (43). VDR ligands prevent 
the activation, differentiation, maturation and survival of APCs, leading to T cell 
hyporesponsiveness(44). Calcitriol also increased the expression of IL-10 and decreased the 
expression of IL-12, two major cytokines that are involved in Th1-Th2 balance(45).  
Several studies have shown that calcipotriol as well as calcitriol and tacalcitol are 
efficacious, safe and can be used on a long-term basis for psoriasis (43, 46-49). Vitamin D3 
analogs can be used in combination with phototherapy(50).  
2.4 Vitamin D status in patients with psoriasis 
Few studies on vitamin D status and its role in psoriasis have been performed or published. 
Low vitamin D status is associated with an increased risk of cancer, autoimmune, infectious, 
and inflammatory diseases, although the role of vitamin D status in the pathogenesis of 
psoriasis is unknown.  
3. The effects of phototherapy on vitamin D status in patients with psoriasis  
A similar wavelength spectrum of UVB is responsible for vitamin D synthesis (280-315 nm), 
which has been successfully used for years to treat psoriasis and other chronic inflammatory 
skin disorders. 
Phototherapy (broadband UVB, narrowband UVB and heliotherapy - treatment with natural 
sunlight) is an effective treatment, commonly used for widespread psoriasis. Therefore, 
phototherapy is an excellent option for patients with generalized psoriasis because of its 
superior systemic safety profile in comparison to systemic and biologic agents (51).  
In addition to standard broadband ultraviolet radiation B (BUVB), (280-315 nm), 
narrowband phototherapy (NBUVB) (monochromatic UV between 311-312 nm) and 
heliotherapy (treatment with natural sunlight) have become important treatment modalities 
for psoriasis. Research suggests that NBUVB is more effective than broadband UVB for 
reducing PASI scores, as well as being a safer and better tolerated option for patients in 
comparison to PUVA when taken at suberythemogenic doses (52). Furthermore, these 
advantages along with the handling ease of the NBUVB lamp led to a reduction in the usage 
of broadband UVB. However, one drawback of the new lamp is that the radiation times 
have almost doubled (54). Additionally, several studies indicate that combination therapy 
using both calcipotriol and UVB radiation illustrate more rapid healing of psoriasis when 
compared to monotherapy of either treatment (50,55).  
Serum levels of 25(OH)D increased during treatment with artificial UV (BUVB and  
NBUVB) and during heliotherapy(56-59). The increase in 25(OH)D was higher in the BUVB 
treated patients when compared to the NBUVB (p=0.008)  and heliotherapy (p=0.017) 
treated groups. Low-dose NBUVB treatment significantly increased vitamin D status in 
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patients with psoriasis, atopic eczema and other skin disorders with low initial levels of 
25(OH)D(60, 61). Within the following intervention studies, age showed no correlation with 
the observed increase in 25(OH)D levels (57, 58, 62). This indicates the skin’s capacity to 
produce vitamin D3 during phototherapy of psoriasis is independent of the patient’s age or 
psoriasis severity. Phototherapy of psoriasis is the time-consuming procedure long enough 
to provide adequate cutaneous production of vitamin D even in elderly patients. The ability 
of the skin to produce vitamin D declines with age (63) due to insufficient sunlight exposure 
(11, 64) and a reduction in the functional production capacity of the skin(63, 65, 66). The 
increase in 25(OH)D3 was enhanced in patients with low baseline levels of vitamin D. 
Vitamin D production in patients with psoriasis increased less with NBUVB than with 
BUVB phototherapy(58). One explanation might be that the optimal wavelength for 
initiation of the vitamin D3 pathway was 300±5 nm in vitro and in vivo(67, 68) which is in 
the BUVB range (280-315 nm). The synthesis of vitamin D was stimulated by wavelengths 
between 290-315 nm, but not for wavelengths longer than 315 nm. One study (58) reported 
that a wavelength of 311 nm effectively induced vitamin D synthesis, but not to the same 
extent as wavelengths in the BUVB range. UVB treatment including NBUVB treatment of 
psoriasis was a sufficiently time-consuming procedure to increase vitamin D. The time 
required for NBUVB to have an effect can reduce the difference in the potential of vitamin D 
production between the two lamps. The treatment time correlated strongly with the type of 
lamp (patients treated with NBUVB required 4 times the exposure patients treated with 
BUVB needed). This is consistent with other studies demonstrating that the dose response of 
the erythemal spectra of NBUVB should be about 4.2 times that of BUVB(69). The dose of 
UVB also correlated with the type of lamp, but no correlation between the dose of UVB and 
the increase of 25(OH)D3 levels was found (58). This might be due to the fact that serum 
concentrations of 25(OH)D3 were measured at different time points and a plateau level was 
reached after three weeks, which was also seen in a previous study(70). An in vitro study 
demonstrated that the dose-response relationship of UV exposure and cholecalciferol 
synthesis was nonlinear. It was hypothesized that exposure to additional UV did not result 
in a proportional increase in vitamin D levels(71). This might be explained by 
autoregulation of the skin synthesis, storage, and slow, steady release of vitamin D3 from 
the skin into the circulation(3). Non-linear vitamin D synthesis is easily explained by the 
photo equilibrium that is set up as a result of continued exposure to ultraviolet radiation as 
reported by Holick et al(72). Vitamin D production is a unique, autoregulated mechanism 
which occurs at two levels. Excessive sun exposure does not lead to overdosing of vitamin 
D3 due to conversion of previtamin D3 to inactive photoproducts (lumisterol 3 and 
tachisterol 3) as well as conversion of vitamin D3 to its isomers in the skin (5,6-trans vitamin 
D3, suprasterol I, suprasterol II) which are thought to have a low calcemic effect at 
physiological concentrations. The synthesis of previtamin D3 reached a plateau at about 10 
to 15 percent of the original 7-dehydrocholesterol content(72). Vitamin D3 is synthesized in 
the skin and released steadily and slowly from the skin into the circulation(3).  
In a study by Ryan, the number of exposures to NBUVB was the sole predictor of an 
increase in serum 25(OH)D level, whereas prior phototherapy was the only predictor of 
baseline serum 25(OH)D levels in the group of psoriasis patients treated with 
phototherapy(73). 
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Patients with lower 25(OH)D levels at baseline responded better to sunlight and 
phototherapy which is consistent with other studies(3, 6, 57). All patients reached serum 
levels of 30 ng/ml (75 nmol/l) after two weeks of sun exposure(62). A circulating level of 
25(OH)D of >30 ng/ml, or >75 nmol/L, appears to be necessary to maximize the health 
benefits of vitamin D(6).  
Sun exposure is the major source of vitamin D for most humans(6). During the winter 
months vitamin D production is insufficient to meet the optimal requirements in both 
younger and older adults at Northern latitudes(74). Psoriasis lesions usually worsen during 
winter, and many patients are therefore given repeated UVB treatment during this season. 
In addition to healing psoriatic lesions, UVB therapy also provides these patients with 
vitamin D during the winter months, when levels of 25(OH)D in Northern countries are 
generally low. UVB therapy even increased serum 25(OH)D levels in patients taking vitamin 
D supplements. This is in line with previous studies, which reported that UV-induced 
vitamin D synthesis had a greater influence on the serum levels of circulating calcidiol than 
the per oral intake of supplements(75, 76).  
Skin pigment, sunscreen use, aging, time of day, season, and latitude all affect previtamin 
D3 synthesis(18). There was no difference in the increase of 25(OH)D between the different 
skin types in the present studies(59). This was most likely due to subjects being exposed to 
individually adjusted doses of UVB depending on skin phototype and erythemal response 
to therapy. All patients had previously experienced UVB therapy for their psoriasis disease. 
As expected, fair-skinned patients required lower doses of UVB (broadband and 
narrowband) than patients with skin type III and IV. This finding is consistent with other 
studies examining the effect of skin pigmentation on vitamin D synthesis(77). Melanin 
pigment in human skin competes with, and absorbs  UVB photons responsible for the 
vitamin D synthesis(77). 
The increase in 25(OH)D during the first two weeks of heliotherapy was very similar to the 
increase in 25(OH)D during treatment with BUVB and NBUVB for two to three months. The 
correlation between sunlight measures and serum 25(OH)D is evidently weak(78). Patients 
reached their plateau of daily sun exposure after the first week. It is likely that vitamin D 
production was most prominent during the first week, when the patients experienced 
redness and some of them even got sunburned(56).  
The increase in 25(OH)D during 15 days of climate therapy was significant even though 
patients used sunscreen on body sites susceptible to sunburn, and though the skin was 
affected by psoriasis lesions(56, 62). This indicates that short-term therapeutic UVB 
exposures are sufficient to increase vitamin D synthesis in psoriasis patients. SPF-8 
sunscreen has been observed to reduce the skin's production of vitamin D3 by 95%(79). 
Clothing also completely blocks all solar UVB radiation and thereby prevents vitamin D3 
production(79).  
Psoriasis improved in all patients, with a reduction in the PASI score of about 75% on all 
regimens(59, 73). Improvement in psoriasis correlated positively with the increase in 
25(OH)D3 levels in one (58) (p=0.047; the group of patients treated with BUVB and  
NBUVB) but not in the other studies (57, 61, 62, 73). There was no correlation between 
change in serum 25(OH)D levels and change in PASI or change in DLQI in the study of 
psoriasis patients treated with NBUVB in Ireland(73). No relationship was found between 
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levels of 25(OH)D and psoriasis but a negative correlation was found between the severity 
of psoriasis and the basal serum level of 1,25(OH)2D(80).  
The skin is the only tissue yet known in which the complete UVB-induced pathway from 7-
DHC via intermediates (previtamin D3, vitamin D3, 25(OH)D) to the final product 
1,25(OH)2D, takes place under physiological conditions(81), (Figure 1). Levels of 
1,25(OH)2D tended to increase during phototherapy, but significant increases were noticed 
only during heliotherapy, and only in women with 25(OH)D3 below 30 ng/ml, and in ages 
≥ 70 years. One explanation might be that these patients had lower serum concentrations of 
25(OH)D at the start of the treatment.  
UVB
Cholecalciferol
(Vitamin D3)
7-Dehydrocholesterol
Liver
25-hydroxyvitamin  D3
Kidney
1,25-dihydroxyvitamin  D3
Vitamin D3
Vitamin D
2
Dietary intake
Maintains calcium balance 
in the body
Skin
Vitamin  D metabolism
1,25(OH)2D
Extra-renal cells 1α-OHase
Promoted differentiation and Inhibited  
proliferation of keratinocytes
Immunomodulation
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Fig. 1. Schematic outline of vitamin D metabolism and mechanism of action in psoriasis. 
It has been postulated that the synthesis of 1,25(OH)2D is tightly regulated, and that 
increases in 25(OH)D concentrations due to exposure to sunlight have no effect on serum 
1,25(OH)2D levels(6, 82). The observation that both 25(OH)D and 1,25(OH)2D increased in 
vitamin D deficient subjects following UVB exposure(83) or after vitamin D 
supplementation(84) has been reported previously. The increase of 1,25(OH)2D levels 
between patients treated with heliotherapy and patients treated with NBUVB differed 
(p=0.02). This might be explained by lower values of 25(OH)D at baseline in patients treated 
with heliotherapy(59). 
Keratinocytes are capable of producing a variety of vitamin D metabolites, including 
1,25(OH)2D, 24,25(OH)2D, 1,24,25(OH)3D(85) from exogenous and endogenous sources of 
25(OH)D. Thus, the local UVB-triggered production of calcitriol may primarily regulate 
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epidermal cellular functions in an auto- and paracrine manner, but this should not be crucial 
for systemic vitamin D effects (5) and systemic vitamin D deficiency does not stimulate 
epidermal synthesis of 1,25(OH)2D(86).  
Cutaneous production of 1,25(OH)2D3 may regulate growth, differentiation, apoptosis and 
other biological processes in the skin(87, 88). Therefore, topical vitamin D analogs have been 
used as a safe and effective treatment for psoriasis vulgaris(89, 90). The NBUVB has been 
shown to have less capacity to induce a local skin production of 1,25(OH)2D3 at 44% of the 
monochromatic irradiation at 300 ±2.5 nm(68). Nevertheless, the known therapeutic effect of 
UVB light therapy for the treatment of psoriasis may be mediated via UVB-induced 
production of 1,25(OH)2D(81). In vitro studies have shown that the substrate concentration 
of cholecalciferol in keratinocytes mainly determines the synthesis rate of 1,25(OH)2D in 
these cells(91). Thus, higher synthesis rates of cholecalciferol should result in a faster and 
more pronounced release of 1,25(OH)2D into the extracellular fluid. UVB-induced 
membrane damage to epidermal keratinocytes may also increase the outflow of newly 
synthesized calcitriol(92).  
It is not clear if the serum 25(OH)D level is linked to the level of the active form of vitamin 
D3 present in the skin. It has been suggested that cutaneous conversion of 25(OH)D to 
1,25(OH)2D does not play a role because the amount of free 25(OH)D3 that penetrates the 
cell membrane of epidermal keratinocytes is too small to produce sufficient amounts of 
1,25(OH)2D(88). The main form of circulating 25(OH)D is presented in a complex with 
vitamin D-binding protein (DBP) with only a very small amount (0.03%) available as the free 
form. Furthermore, the deeper layers of the epidermis are not vascularized, which further 
impairs the passage of the 25(OH)D3-DBP complex from blood to epidermal 
keratinocytes(88).  
The receptor for calcitriol and the production of 1,25(OH)2D vary with the differentiation 
in a manner suggesting feedback regulation, and both are reduced in the later stages of 
differentiation(93). 1,25(OH)2D increases involucrin, transglutaminase activity, and 
cornified envelope formation in preconfluent keratinocytes(94). NBUVB treatment 
increases cathelicidin and decreases HBD2 levels in healing skin lesions of psoriasis and 
atopic dermatitis(61). It has been shown that HBD2 and cathelicidin expression in 
psoriatic skin are higher in serum vitamin D sufficient patients than in serum vitamin D 
deficient psoriasis patients(95). 
The 1,25(OH)2D molecule and its analogs, as well as UVB phototherapy, exert 
antiproliferative, prodifferentiative, and immune-modulatory effects on keratinocytes that 
are of particular importance for the therapy of hyperproliferative skin diseases such as 
psoriasis vulgaris(5, 96). However, the full range of UVB and vitamin D3 effects is not 
completely understood.  
4. Serum PTH in psoriasis patients during treatment with phototherapy 
PTH decreased after the treatment with phototherapy(57). 25(OH)D concentrations below 30 
ng/ml (75 nmol/l) resulted in secondary hyperparathyroidism and a decrease in BMD(97). 
PTH increases with increasing age, possibly due to less sunlight exposure and/or reduced 
calcium/vitamin D intake(98). The clear concomitant decrease in serum PTH after UVB 
exposure indicates that the skin’s capacity to synthesize vitamin D is maintained even at 
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older ages and with part of the skin covered by psoriatic lesions. Serum concentrations of 
calcium and creatinine were unaltered after phototherapy(58). 
5. Bone status in patients with psoriasis treated with UVB phototherapy 
Multiple risk factors that contribute to low serum 25(OH)D and osteoporosis have been 
identified. They include inadequate sun exposure(99), insufficient intake of fortified foods or 
vitamin D supplements(100), low body mass index, white ethnicity, lack of exercise, use of 
medications that accelerate vitamin D metabolism, diseases that alter vitamin D metabolism 
such as malabsorption syndromes, and chronic liver disease(9, 13, 101).  
Information regarding the prevalence of osteoporosis in addition to the epidemiological 
study of risk factors for developing osteoporosis among psoriasis patients has been sparse 
and controversial. Psoriasis patients with or without arthritis may suffer from 
osteoporosis(102). However, a previous study showed that patients with chronic plaque 
psoriasis had a low BMD despite risk factors, although the subgroup with joint involvement 
appeared to be at a higher risk of developing osteoporosis and therefore required 
prevention therapy(103). Reduced BMD has been linked to palmoplantar pustular 
psoriasis(104). The existence of less severe periarticular osteoporosis has also been 
reported(105). Psoriasis patients with peripheral arthritis with longer duration of joint 
disease(106) and patients with a greater number of affected joints are at a higher risk of 
developing osteoporosis(102).In a study by Pedreira, patients with psoriasis and psoriatic 
arthritis did not present with a lower BMD, but they had a higher prevalence of osteoporotic 
fractures and were at a higher risk of developing metabolic syndrome(107).  
Postmenopausal women with psoriasis treated with phototherapy had higher BMD of both 
the hip and lumbar spine compared with age-matched controls (57, 108). In the same 
study(108), patients with 25(OH)D levels below 30 ng/ml and secondary 
hyperparathyroidism had lower BMD in terms of both T and Z scores of the hip and the 
lumbar spine compared with those with higher vitamin D levels, consistent with another 
study(109). No relationship between psoriasis onset and bone status was found. Higher 
body weight and BMI are factors, which may have contributed to the higher BMD in 
patients(108) compared with controls 
In general, bone loss increases with age. BMD has been shown to be a predictive indicator 
for bone fractures in healthy subjects and in patients with osteoporosis(111). 
A family history of fractures, physical activity, smoking and estrogen substitution are 
important factors influencing bone mass(112-114). Low body weight is related to low 
skeletal muscle mass and an increased risk of fractures(114, 115). Muscle tissue and strength 
are important for body balance and the prevention of falls(116). Previous studies confirm the 
protective effect of weight gain against fractures(17).  
Physical activity correlated positively with BMD in psoriasis patients(108). Physical activity 
has been claimed to be beneficial for bone mass and protective against fractures(117). 
Regular walking in middle-aged and elderly women is associated with a reduced risk of 
vertebral deformity(118). Subjects who took a daily walk of at least 30 min had a 
significantly better climbing capacity, higher BMD and lower concentration of serum 
triglycerides than subjects who walked less(119). Lifetime exercise was also positively 
associated with BMD of the hip(120). 
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Vitamin D is important for bone metabolism(121). Vitamin D deficiency thus contributes to 
the pathogenesis of osteoporosis and hip fractures(122). Supplementation strategies 
involving calcium and vitamin D supplements are cost-effective for preventing osteoporotic 
fractures(123). 
The same range of UVB (290–315 nm) that induces vitamin D synthesis also improves 
psoriasis. Treatment with UVB in patients with psoriasis is most common during winter 
months when UVB is lacking, and levels of vitamin D are low in Northern countries(123). 
Furthermore, UVB therapy heals psoriasis and supplies these patients with vitamin D at 
levels similar to those of the general population(123), which might have positive effects on 
bone status as well. 
6. Blood glucose and lipid status in psoriasis patients during treatment with 
heliotherapy  
Psoriasis is considered a chronic and debilitating inflammatory disease associated with 
serious comorbidities (124, 125). Large epidemiological studies have shown that psoriasis 
and psoriatic arthritis are associated with metabolic diseases including obesity, dyslipidemia 
and diabetes(126). The chronic inflammation in psoriasis can predispose patients to other 
inflammatory conditions. The proinflammatory cytokines, such as tumor necrosis factor- 
(TNF-), and other factors that are overproduced in patients with psoriasis likely contribute 
to the increased risk for the development of metabolic syndrome(127, 128).  
Inflammatory factors have also been associated with insulin resistance and ǃ-cell failure, 
both of which are key features of type 2 diabetes mellitus (129). There is evidence that 
vitamin D may stimulate pancreatic insulin secretion directly through nuclear receptors that 
are found in a wide variety of tissues, including T and B lymphocytes, skeletal muscle, and 
the pancreatic islet  ǃ-cells(130). There is some evidence that suggests increased PTH activity 
is associated with, and possibly causes, reduced insulin sensitivity(130). The prevalence of 
impaired glucose tolerance and diabetes mellitus is increased in patients with primary 
hyperparathyroidism (131, 132). 
Vitamin D has a wide range of effects on the immune system: it promotes the differentiation of 
monocytes into macrophages thus increasing their cytotoxic activity; reduces the antigen-
presenting activity of macrophages to lymphocytes; prevents dendritic cell maturation; 
inhibits T lymphocyte-mediated immunoglobulin synthesis in B cells and inhibits delayed-
type hypersensitivity reactions(8, 133, 134). Furthermore vitamin D has been reported to 
down-regulate the production of several cytokines: IL-2, IL-6 and IL-12, interferon-Ǆ, TNF-ǂ, 
and TNF-ǃ (134, 135). Alternations in vitamin D status and/or action may affect insulin 
sensitivity, ǃ-cell function or both. Therefore, vitamin D may be involved in the pathogenesis 
of type 2 diabetes mellitus at both environmental and genetic levels(129). Psoriasis patients are 
more likely to be insulin resistant and to have impaired glucose tolerance, higher fasting 
insulin levels, and impaired ǃ-cell function than non-psoriatic subjects(136).  
Heliotherapy improves lipid and carbohydrate status of psoriasis patients(56). Increases in 
high-density lipoprotein (HDL)-cholesterol and decreases in HbA1c during climate therapy 
could be explained by several factors. One possible mechanism could be a direct effect of 
vitamin D on insulin sensitivity(130). Another is that sun exposure usually implies greater 
outdoor physical activity, leading to beneficial effects on lipids and insulin sensitivity, 
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unrelated to serum 25(OH)D concentrations(130). Diet might also influence glucose and 
lipid metabolism. Although climate therapy did not change the basal glucose levels of the 
patients, the HbA1c levels decreased about 10 %, indicating improved insulin sensitivity 
(56). The observed associations between vitamin D, insulin, and glucose metabolism in 
humans have not yet been confirmed by intervention studies and, hence, a causal 
association has not been established(130).  
A high prevalence of atherosclerosis is also reported in psoriasis patients. High serum lipid 
levels have been suggested in the pathogenesis of atherosclerosis. High serum lipid levels 
are more common in psoriasis and may be responsible for an elevated prevalence of 
cardiovascular accidents in this group of patients(137). Patients with psoriasis exhibit a 
dyslipidemic profile, including increased levels of plasma cholesterol, triglycerides (TG), 
LDL, very low-density lipoprotein (VLDL) cholesterol and decreased levels of HDL 
cholesterol. Lipid abnormalities in psoriasis patients may be genetically determined(138). 
The ratio of low-density lipoprotein cholesterol (LDL) and high-density lipoprotein 
cholesterol (HDL) decreased, and the levels of hemoglobin A1c (HbA1c) also decreased in 
psoriasis patients during heliotherapy(56). Serum concentrations of 25(OH)D at baseline in 
psoriasis patients treated with heliotherapy correlated positively with serum HDL at 
baseline(56), consistent with a previously published study(139).  
Psoriasis is associated with obesity, which is a component of metabolic syndrome. Obesity 
has been shown to be an independent risk factor for the development of psoriasis, and is 
also associated with more severe psoriasis (140). Abdominal obesity is a proinflammatory 
state with the visceral adipose tissue providing a rich source of inflammatory molecules 
known as adipocytokines including leptin, adiponectin, visfatin and resistin. This may 
explain an important association between obesity, insulin resistance and related 
inflammatory disorders.  
Inflammation plays a key role in the pathogenesis of psoriasis and a number of chronic 
inflammatory systemic diseases listed above. Activated inflammatory cells and pro-
inflammatory cytokines, such as TNF-ǂ and IL-1ǃ, contribute to the development of 
psoriatic lesions and play an important role in atherosclerosis (141).  
7. Conclusion 
Recent literature has provided plenty of information concerning the preventive and 
therapeutic role of vitamin D in many inflammatory diseases including psoriasis. Vitamin D 
inhibits proinflammatory processes by suppressing the enhanced activity of immune cells 
that take part in the autoimmune reaction. Phototherapy (UVB and heliotherapy) improved 
psoriasis and lipid and carbohydrate status of the patients, increased serum 25(OH)D 
synthesis and reduced serum PTH concentrations. UVB therapy heals psoriasis and supplies 
these patients with vitamin D, which might have positive effects on bone status as well. 
The beneficial role of vitamin D for psoriasis might be due to both a skin and systemic increase 
in vitamin D metabolism. Cutaneous 1,25(OH)2D generated in psoriatic skin after UVB 
exposure develops a growth-inhibitory effect on proliferating epidermal keratinocytes similar 
to topically applicated calcitriol. It is unknown if skin affected by diseases such as psoriasis or 
eczema differ in vitamin D production compared to normal skin. Further research is needed to 
achieve a more comprehensive understanding of the synthesis of vitamin D in psoriatic skin 
and the role of vitamin D status in the prevention and treatment of psoriasis.  
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